A retrospective analysis of patient outcome according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model from a phase III trial of sunitinib versus interferon-a as treatment for metastatic renal cell carcinoma was performed; IMDC benchmarks from this analysis for objective response rate, progression-free survival, and overall survival for sunitinib-treated patients are reported. Background: Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. In this analysis we report benchmarks for clinical outcomes on the basis of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups for patients treated with sunitinib for mRCC in a first-line setting. Materials and Methods: A retrospective analysis was performed on data from sunitinib-treated patients (n ¼ 375) in the pivotal phase III trial of sunitinib versus interferon-a as first-line treatment for mRCC. Objective response rates (ORRs) were determined from independently reviewed radiologic assessments. The KaplaneMeier method was used to estimate median progression-free survival (PFS) and median overall survival (OS) according to patient risk group. Results: Median PFS (95% confidence interval [CI]) was 14.1 (13.4-17.1), 10.7 (10.5-12.5), 2.4 (1.1-4.7), and 10.6 (8.1-10.9) months in sunitinib-treated patients in the IMDC favorable (n ¼ 134), intermediate (n ¼ 205), poor (n ¼ 34), and intermediate þ poor (n ¼ 239) risk groups, respectively. Median OS (95% CI) was 23.0 (19.8-27.8), 5.1 (4.3-9.9), and 20.3 (16.8-23.0) months in sunitinib-treated patients in IMDC intermediate, poor, and intermediate þ poor risk groups, respectively, and was not reached in the favorable risk group (>50% of patients were alive at data cutoff). ORRs (95% CI) was 53.0% (44.2%-61.7%), 33.7% (27.2%-40.6%), 11.8% (3.3%-27.5%), and 30.5% (24.8%-36.8%) in sunitinib-treated patients in IMDC favorable, intermediate, poor, and intermediate þ poor risk groups, respectively. Conclusion: Results of this retrospective analysis show differences in patient outcomes for PFS, OS, and ORR on the basis of IMDC prognostic risk group assignment for patients with mRCC.
Introduction
Over the past decade, the prognosis for patients with metastatic renal cell carcinoma (mRCC) has been improved by the development of molecularly targeted drugs, including those that target vascular endothelial growth factor. [1] [2] [3] In the course of clinical trials aimed at advancing treatment of mRCC, knowledge of patient profiles and outcomes has been compiled, allowing investigators to develop models for stratification of patients according to risk on the basis of readily available biological factors. 4, 5 Risk stratification is widely used for patient counseling and in the design of clinical trials. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model, first proposed and validated by Heng et al in 2009, was specifically developed using patient data of molecularly targeted cancer therapies. 6 The model uses 6 readily available factors (diagnosis to treatment time interval, Karnofsky Performance Status [KPS] , hemoglobin level, platelet count, neutrophil count, and serum calcium concentration) to classify patients into favorable (0 risk factors), intermediate (1 or 2 risk factors), and poor (3 risk factors) risk prognostic groups. 6 The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic model has also been used to stratify patients according to risk. The MSKCC model, proposed in 2002, was developed from clinical data and patient profiles from multiple trials of interferon-a (INF-a) as a first-line treatment for mRCC. This model includes 5 factors, 4 of which are shared with the IMDC model: time from diagnosis to treatment, KPS, hemoglobin, and serum calcium. The MSKCC model also includes serum lactate dehydrogenase concentration as a factor. Similar to the IMDC model, the MSKCC model has also been used to stratify patients into favorable, intermediate, and poor risk groups. 7 Sunitinib malate, a globally approved, multitargeted, tyrosine kinase inhibitor, has become a reference standard of care for mRCC, and serves as the active comparator in multiple mRCC clinical trials in which enrollment might be restricted to prespecified, prognostic risk groups. [8] [9] [10] [11] [12] Notably, 2 recently reported randomized trials using sunitinib as the standard arm focused on IMDC intermediate-and poor-risk populations and reported clinical outcomes specifically in this population. 12, 13 The interpretation and analysis of current and future clinical trials involving sunitinib treatment in patients with mRCC would be aided by the availability of benchmarks for patient responses to sunitinib treatment on the basis of IMDC risk group, because use of this model has increasingly become the default choice for patient risk stratification in investigations of targeted therapies. To produce these benchmarks, a retrospective analysis of outcome from a pivotal phase III clinical trial comparing sunitinib with INF-a in patients with mRCC 14 was performed according to IMDC risk group. Patients from this trial had been previously stratified for risk using the MSKCC model 1 because earlier analyses of data were performed before the introduction and routine use of the IMDC prognostic model.
Materials and Methods

Study Design
A retrospective analysis was performed on data from an international, multicenter, randomized, phase III trial of sunitinib versus INF-a as first-line treatment for mRCC. 1 Benchmark values for these outcomes according to IMDC risk groups were derived from independently reviewed radiologic tumor progression measurements from the intent to treat (ITT) population. A supportive analysis of data from investigator measurements of tumor progression was also performed according to IMDC risk group. For the purpose of additional comparison, the independently reviewed radiologic data for patient outcomes and overall survival (OS) were also analyzed according to MSKCC risk groups.
In the clinical trial, treatment-naive patients with mRCC (with a clear-cell component) in all prognostic risk groups were randomized into 2 separate arms and treated with sunitinib or INF-a. 1 Tumor assessments, response, and progression were defined according to Response Evaluation Criteria in Solid Tumors version 1.0 criteria and evaluated by an independent, third-party radiology laboratory; clinical trial investigators performed supplemental tumor assessment.
Tumor assessment was performed on day 28 (28-day cycle) of cycles 1 to 4, and every 2 cycles thereafter until the end of treatment for patients receiving sunitinib. The primary efficacy end point was progression-free survival (PFS); secondary study end points included objective response rate (ORR) and median OS, all in the ITT population. Benchmark values are reported for these data. Complete details of the clinical study design, including patient population data and inclusion/exclusion criteria, were reported previously.
1,14
Statistical Methods
All efficacy end points were assessed in the ITT population. The primary end point of the study (PFS assessed by independent radiology review committee) and secondary study end points have been reported previously. 1 
Results
Patients
A total of 750 patients were enrolled for the clinical trial at 101 centers in multiple countries including the United States. Of these, 375 patients were randomized to the sunitinib treatment arm. All 375 patients in the sunitinib group received at least 1 dose of the study drug. 1 Median duration of treatment for sunitinib-treated patients during the period analyzed was 6 months (range, 1-15 months), and patients were followed for at least 28 days after their last dose. 1 Baseline demographic and disease characteristics for sunitinib-treated patient are shown in Table 1 . Table 2 (on the basis of independent radiology laboratory data) and Table 3 (on the basis of investigator measurements). In both data sets, median PFS was different (ie, no overlap of the 95% CI for the values) between the 3 main risk groups. Median PFS was longest for the favorable-risk group and progressively shorter for the intermediate-and poorrisk groups, as expected. This order in degrees of treatment response was also seen in ORR, although there was overlap of 95% CIs for the response values of the intermediate-and poor-risk groups with independent radiology laboratory data as well as investigator assessment data; there was also an overlap between the favorable-and intermediate-risk groups in the investigator assessment data. On the basis of independent radiology laboratory data the PFS (95% CI) was 10.6 months (4.2%-11.8%) for patients with bone metastases, which was not different from PFS for patients without bone metastases at 10.7 months (8.1%-11.1%).
Efficacy According to IMDC and MSKCC Risk Groups
Median Table 4 . As with the patients stratified using the IMDC, the median PFS was 
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Clinical Genitourinary Cancer August 2018 -301 different between the 3 main risk groups; median PFS was longest for the favorable-risk group and shortest for the poor-risk group with no overlap of 95% CIs for the PFS values for the 3 groups. ORR was highest in the favorable-risk group and was progressively lower in the intermediate-and poor-risk groups with overlap of 95% CIs between these latter 2 groups. These results are similar to the findings (on the basis of the same independent radiology laboratory data) with patients stratified using the IMDC. The KaplaneMeier plots for PFS estimation for patients with IMDC classifications of favorable risk, intermediate-1 risk, intermediate-2 risk, and poor risk on the basis of independent radiology laboratory data ( Figure 2 ) and investigator measurements (Figure 3 ) are shown.
Median OS benchmark values for sunitinib-treated patients according to IMDC and MSKCC risk group are shown in Table 5 . Because most favorable-risk patients were still alive at the time of data cutoff, median OS was not determined for this group. For groups stratified using IMDC there was a marked difference in median OS between the intermediate-risk and poor-risk groups, with no overlap of 95% CIs. There was also a difference in median OS between the patients classified as intermediate-1 risk versus intermediate-2 risk, with no overlap of 95% CIs.
Discussion
The MSKCC and IMDC models are both currently used to determine patient risk group for the purpose of patient counseling, Figure 3 
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clinical trial design, and data interpretation.
the more recently derived of the 2 models, having been developed after the emergence of molecularly targeted therapies as the standard of care for mRCC. 16 The IMDC model has been extensively validated for risk stratification of patients treated with targeted therapy in first-line as well as second-line settings. 17, 18 The benchmark values for PFS, ORR, and OS on the basis of independent radiology laboratory data are broadly similar for IMDC-and MSKCC-stratified risk groups across all risk classifications for this population of 375 patients receiving first-line sunitinib treatment for mRCC. The similar number of patients in this study classified as intermediate and poor risk using the IMDC compared with the MSKCC model is consistent with previous studies. 16, 19 The analysis suggests that IMDC and MSKCC models might have comparable prognostic value when applied to cohorts similar to the one examined in this study. This study has certain limitations; first, it is limited by nature of being a retrospective post hoc analysis. In addition, the original clinical trial design and patient recruiting were conducted before the introduction of the IMDC model, which should be considered when comparisons are made with trials designed and run after use of the IMDC model became routine. The OS data from this study are no longer contemporary in light of developments in the post-disease progression setting, particularly those changes due to the emergence of immune oncology therapies.
Conclusion
This retrospective analysis provides benchmarks for median PFS, median OS, and ORR for treatment responses in mRCC according to IMDC. These benchmark values can aid current and future design and interpretation of clinical trials in mRCC. Results of this analysis show clear differences in patient outcomes on the basis of IMDC prognostic risk group. For all risk groups, PFS, ORR, and OS were broadly similar in the IMDC-and MSKCC-stratified groups within this study. 
Clinical Practice Points
Results of this study suggest there might be significant prognostic differences between the intermediate-1 and intermediate-2 IMDC risk groups and that this should be considered when counseling patients identified to be in one of these groups. Some differences in ORR were seen depending on whether independently reviewed radiologic assessments or investigator assessments were used to derive outcomes. These differences are possibly because of investigator bias and/or the nonuniformity of treatment centers that participated in this study. The clinical outcomes on the basis of independent radiology laboratory data are broadly similar for the IMDC-and MSKCCstratified risk groups across all risk classifications in this study. This supports the continued usage of either model in stratifying patient risk for counseling purposes.
